A1SN34 Stock Overview
A biopharmaceutical company, focuses on developing therapies for unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Ascendis Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$45.10 |
| 52 Week High | US$52.90 |
| 52 Week Low | US$27.62 |
| Beta | 0.59 |
| 11 Month Change | -6.86% |
| 3 Month Change | -6.86% |
| 1 Year Change | 63.29% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 27.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| A1SN34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | 0% | 1.3% | 1.8% |
| 1Y | 63.3% | 5.5% | -2.1% |
Return vs Industry: A1SN34 exceeded the BR Biotechs industry which returned 5.5% over the past year.
Return vs Market: A1SN34 exceeded the BR Market which returned -2.1% over the past year.
Price Volatility
| A1SN34 volatility | |
|---|---|
| A1SN34 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in BR Market | 9.1% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: A1SN34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine A1SN34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 879 | Jan Mikkelsen | ascendispharma.com |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Ascendis Pharma A/S Fundamentals Summary
| A1SN34 fundamental statistics | |
|---|---|
| Market cap | R$41.90b |
| Earnings (TTM) | -R$2.96b |
| Revenue (TTM) | R$1.94b |
22.1x
P/S Ratio-14.5x
P/E RatioIs A1SN34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A1SN34 income statement (TTM) | |
|---|---|
| Revenue | €329.02m |
| Cost of Revenue | €47.34m |
| Gross Profit | €281.68m |
| Other Expenses | €783.25m |
| Earnings | -€501.57m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.75 |
| Gross Margin | 85.61% |
| Net Profit Margin | -152.44% |
| Debt/Equity Ratio | -239.8% |
How did A1SN34 perform over the long term?
See historical performance and comparison